Dyspepsia Drugs Market - Indication (Functional, Organic), Drug Type (Proton Pump Inhibitors, H-2-Receptor Antagonists, Antacids, Antibiotics), Medication (Branded, Generic), Mode (OTC, Prescription), Distribution Channel, Global Forecast (2024-2032)

Dyspepsia Drugs Market Size

Dyspepsia Drugs Market size accounted for USD 9.7 billion in 2023 and is set to register 4.5% CAGR between 2024 and 2032. The robust growth of this market is majorly attributed to factors such as increasing prevalence of dyspepsia, growing aging population, and rising preference for over the counter (OTC) drugs/medications.
 

For instance, according to the Journal of Neurogastroenterology and Motility (JNM), the prevalence of functional dyspepsia is estimated to be around 10-40% in western countries, and about 5-30% in Asia. Thus, as the prevalence of dyspepsia continues to increase, there is a growing pool of individuals seeking dyspepsia drugs for alleviating the symptom associated with it, thereby augmenting the market expansion. Additionally, the increasing use of proton pump inhibitors (PPIs), and growing research & development activities for development of novel product is expected to support the growth.
 

Dyspepsia drugs encompass a range of medications designed to alleviate symptoms associated with dyspepsia, a condition characterized by discomfort or pain in the upper abdomen often related to digestion. Dyspepsia, also known as indigestion, typically includes symptoms such as bloating, discomfort, and pain in the upper abdomen.
 

COVID-19 Impact

The pandemic had a negative impact on dyspepsia drugs market. The global supply chains for pharmaceuticals faced disruptions due to lockdowns, restrictions on transportation, and challenges in the production and distribution of drugs. This affected the availability of drugs globally. Also, the focus of healthcare systems shifted towards addressing the immediate challenges posed by the pandemic. Non-urgent medical visits, including those related to dyspepsia were postponed, thereby impacting the overall market growth in 2020. However, adoption towards digital health solutions including telemedicine was noted in later half of 2020, resulting in a modest increase in the growth.
 

Dyspepsia Drugs Market Trends

• Dyspepsia is often associated with aging, and its prevalence tends to rise in older populations. Age-related changes in the digestive system, such as reduced stomach acid secretion and changes in gastric motility, can contribute to the development of dyspeptic symptoms. Thus, the increasing demand and utilization of dyspepsia drugs among aging population is expected to support the growth of this market.
   
• Further, over-the-counter drugs, including antacids and PPIs, offer consumers the flexibility to address these symptoms proactively. Therefore, accessibility and availability of OTC dyspepsia drugs in retail pharmacies setting contribute to market expansion.
   

Dyspepsia Drugs Market Analysis

Based on indication, the market is segmented into functional dyspepsia and organic dyspepsia. The functional dyspepsia segment accounted for USD 6.9 billion in 2023.
 

• Functional dyspepsia is one of the most common gastrointestinal disorders, characterized by persistent or recurrent upper abdominal pain or discomfort without an identifiable cause. Its high prevalence makes it a significant target for drug development and treatment strategies. Also, availability of several branded and OTC drugs in the market for treating functional dyspepsia contributes significantly to the global market share.
   

Based on drug type, the dyspepsia drugs market is classified into proton pump inhibitors (PPIs), H-2-receptor antagonists, antacids, antibiotics, prokinetics, and antidepressants. The proton pump inhibitors segment is expected to dominate the market throughout the analysis period.
 

• PPIs are widely prescribed for various acid-related disorders beyond dyspepsia, including gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. Similarly, PPIs have a favorable safety profile when used appropriately. They are well-tolerated by patients and are considered safe for short-term and long-term use in appropriate clinical ways.
   
• Thus, usage of PPIs in such broad spectrum of indications is anticipated to increase their market share.
   

Based on medication, the dyspepsia drugs market is divided into branded and generic. The branded segment is expected to grow at CAGR of 3.4% between 2024 and 2032.
 

• These drugs are often associated with perceived quality and efficacy owing to its extensive research, clinical trials, and post-marketing studies, thereby contribute to the credibility of branded drugs.
   
• Also, branded drugs have improved drug absorption, reduced side effects, or enhanced overall effectiveness, providing an advantage over generic alternatives. Hence owing to these advantages the adoption of branded dyspepsia drugs is high compared to generic drugs.
   

Based on mode, the dyspepsia drugs market is categorized into over-the-counter and prescription. The over-the-counter segment held majority of business share in 2023 and is expected to reach USD 10.3 billion by 2032.
 

• OTC dyspepsia drugs are easily accessible to consumers. This accessibility, cost-effectiveness, and the convenience of purchasing medications directly from pharmacies or retail outlets contribute to a higher market share.
   
• Also, these drugs often provide immediate relief for mild symptoms such as heartburn, indigestion, or bloating. Consumers may prefer OTC options for quick relief without the need for a doctor's visit.
   

Based on distribution channel, the dyspepsia drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment contributed to the significant market share and was valued at USD 4.9 billion in 2023.
 

• Retail pharmacies are widely distributed across urban and rural areas, making dyspepsia drugs easily accessible to a large population. The broad network of retail pharmacies contributes to their ability to reach a diverse consumer base.
   
• Retail pharmacies stock a wide range of over-the-counter (OTC) dyspepsia drugs, providing consumers with immediate access to symptom-relief options. Thus, the availability of wide range of products in retail outlets contributes to the market share.
   

The North America dyspepsia drugs market is expected to reach USD 6.1 billion by 2032 with CAGR of 4.4%.
 

• North America possesses relatively high prevalence of dyspepsia, along with factors such as dietary habits, lifestyle choices, and a higher incidence of gastroesophageal reflux disease (GERD) contribute to the demand for dyspepsia drugs in the region.
   
• The region boasts advanced healthcare infrastructure with well-established healthcare systems, a network of healthcare providers, pharmacy chain and easy access to medical facilities. Similarly, availability of several proton pump inhibitors and antacids in the market along with continually advancements in gastroenterological therapeutic will spur the regional market growth.
   

Dyspepsia Drugs Market Share

The dyspepsia drugs industry is expected to witness dynamic shifts, driven by innovation, changing consumer preferences, and the pursuit of more effective and patient-friendly treatment options. Established players such as AstraZeneca plc, Takeda Pharmaceutical Company Limited, Pfizer, Inc. are prominent contributors, leveraging their diversified portfolio to address dyspeptic symptoms. These companies also invest in research and development to discover novel compounds and formulations for dyspepsia treatment, aiming for improved efficacy and reduced side effects.
 

Dyspepsia Drugs Market Companies

Prominent players operating in the dyspepsia drugs industry are as mentioned below:

• Takeda Pharmaceutical Company Limited
• AstraZeneca plc
• Salix Pharmaceuticals, Inc.
• Abbott Laboratories
• Pfizer Inc.
• Sanofi SA
• Procter & Gamble
• Haleon plc
• ANI Pharmaceuticals, Inc.
• Dr Reddy’s Laboratories Ltd.
   

Dyspepsia Drugs Industry News:

• In July 2023, Acofide (acotiamide) of Meiji Seika Pharma and Zeria Pharmaceutical was approved for treating functional dyspepsia in Thailand. This regulatory approval is expected to enhance company’s geographical outreach.
   
• In February 2020, Dr Reddy’s Laboratories Ltd launched its first-to-market naproxen and esomeprazole magnesium delayed-release tablets. This strategic launch has helped the company to enhance their product portfolio and boost their revenue.
   

The dyspepsia drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Indication, 2018 – 2032 (USD Million)

• Functional dyspepsia
• Organic dyspepsia

By Drug Type, 2018 – 2032 (USD Million)

• Proton pump inhibitors
• H-2-receptor antagonists
• Antacids
• Antibiotics
• Prokinetics
• Antidepressants

By Medication, 2018 – 2032 (USD Million)

• Branded
• Generic

By Mode, 2018 – 2032 (USD Million)

• Over-the-counter
• Prescription

Dyspepsia Drugs Market, By Distribution Channel, 2018 – 2032 (USD Million)

• Retail pharmacies
• Hospital pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa